Is UNCY or FTH more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media prefer UNCY or FTH?

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.96 beat Unicycive Therapeutics' score of 0.31 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FTH or MIST more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Milestone Pharmaceuticals N/A -339.33% -61.79%

Does the media favor HUMA or FTH?

In the previous week, Humacyte had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 5 mentions for Humacyte and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.96 beat Humacyte's score of 0.37 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NGEN or FTH?

NervGen Pharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A -$0.09 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is NGEN or FTH more profitable?

NervGen Pharma's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A Sensei Biotherapeutics N/A -83.59% -256.50%

Which has better valuation and earnings, HURA or FTH?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is HURA or FTH more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Sensei Biotherapeutics N/A -83.59% -256.50%

Does the media prefer HURA or FTH?

In the previous week, TuHURA Biosciences had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 5 mentions for TuHURA Biosciences and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.96 beat TuHURA Biosciences' score of 0.94 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sensei Biotherapeutics (FTH) Competitors

$29.13 -0.11 (-0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$29.36 +0.23 (+0.79%)

As of 04:10 PM Eastern

Compare

FTH vs. UNCY, MIST, HUMA, NGEN, and HURA

Should you buy Sensei Biotherapeutics stock or one of its competitors? MarketBeat compares Sensei Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensei Biotherapeutics include Unicycive Therapeutics (UNCY), Milestone Pharmaceuticals (MIST), Humacyte (HUMA), NervGen Pharma (NGEN), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Sensei Biotherapeutics compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Unicycive Therapeutics currently has a consensus price target of $21.75, indicating a potential upside of 340.28%. Sensei Biotherapeutics has a consensus price target of $54.75, indicating a potential upside of 87.95%. Given Unicycive Therapeutics' higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Sensei Biotherapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	198.98	-$26.56M	-$2.21	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sensei Biotherapeutics' return on equity of -83.59% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.96 beat Unicycive Therapeutics' score of 0.31 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Unicycive Therapeutics and Sensei Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Milestone Pharmaceuticals?

Sensei Biotherapeutics (NASDAQ:FTH) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Sensei Biotherapeutics currently has a consensus price target of $54.75, suggesting a potential upside of 87.95%. Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 577.57%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sensei Biotherapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Sensei Biotherapeutics' return on equity of -83.59% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 3 mentions for Sensei Biotherapeutics and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.87 beat Sensei Biotherapeutics' score of 0.96 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensei Biotherapeutics	Positive
Milestone Pharmaceuticals	Very Positive

Sensei Biotherapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Milestone Pharmaceuticals	$1.55M	85.95	-$63.06M	-$0.68	N/A

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Milestone Pharmaceuticals beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Humacyte presently has a consensus target price of $6.25, indicating a potential upside of 890.96%. Sensei Biotherapeutics has a consensus target price of $54.75, indicating a potential upside of 87.95%. Given Humacyte's higher probable upside, equities analysts plainly believe Humacyte is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Humacyte has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Sensei Biotherapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Sensei Biotherapeutics' return on equity of -83.59% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

In the previous week, Humacyte had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 5 mentions for Humacyte and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.96 beat Humacyte's score of 0.37 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sensei Biotherapeutics has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	68.64	-$40.83M	-$0.57	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

Summary

Humacyte and Sensei Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

NervGen Pharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

NervGen Pharma presently has a consensus price target of $14.00, indicating a potential upside of 769.57%. Sensei Biotherapeutics has a consensus price target of $54.75, indicating a potential upside of 87.95%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe NervGen Pharma is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

NervGen Pharma's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than NervGen Pharma. MarketBeat recorded 3 mentions for Sensei Biotherapeutics and 1 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 1.87 beat Sensei Biotherapeutics' score of 0.96 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
NervGen Pharma	Very Positive
Sensei Biotherapeutics	Positive

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NervGen Pharma beats Sensei Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Sensei Biotherapeutics' return on equity of -83.59% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

In the previous week, TuHURA Biosciences had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 5 mentions for TuHURA Biosciences and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.96 beat TuHURA Biosciences' score of 0.94 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences currently has a consensus target price of $9.00, indicating a potential upside of 322.54%. Sensei Biotherapeutics has a consensus target price of $54.75, indicating a potential upside of 87.95%. Given TuHURA Biosciences' higher probable upside, equities research analysts clearly believe TuHURA Biosciences is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

TuHURA Biosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

Summary

Sensei Biotherapeutics beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTH vs. The Competition

Export

Metric	Sensei Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.24M	$3.71B	$7.04B	$12.13B
Dividend Yield	N/A	2.18%	2.67%	9.43%
P/E Ratio	-0.20	22.08	27.30	23.78
Price / Sales	N/A	162.32	512.96	89.18
Price / Cash	N/A	59.51	26.39	46.66
Price / Book	1.98	7.93	10.27	6.10
Net Income	-$21.08M	$23.81M	$3.60B	$336.45M
7 Day Performance	2.68%	-3.95%	-1.80%	-2.14%
1 Month Performance	27.37%	-4.65%	-2.67%	-3.32%
1 Year Performance	N/A	32.78%	18.21%	13.49%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTH Sensei Biotherapeutics	4.1873 of 5 stars	$29.13 -0.4%	$54.75 +88.0%	N/A	$39.24M	N/A	N/A	40	Upcoming Earnings Analyst Forecast Gap Up
UNCY Unicycive Therapeutics	2.9766 of 5 stars	$5.69 +4.4%	$21.75 +282.2%	+5.3%	$149.29M	$680K	N/A	9
MIST Milestone Pharmaceuticals	2.2422 of 5 stars	$1.23 +4.2%	$7.25 +489.4%	-28.5%	$146.91M	$1.55M	N/A	30	Positive News
HUMA Humacyte	3.6136 of 5 stars	$0.67 +2.2%	$6.25 +831.7%	-73.4%	$145.69M	$2.04M	N/A	150	News Coverage Analyst Forecast
NGEN NervGen Pharma	2.6041 of 5 stars	$1.78 +2.9%	$14.00 +686.5%	N/A	$143.52M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTH) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (FTH) Competitors

FTH vs. UNCY, MIST, HUMA, NGEN, and HURA

How does Sensei Biotherapeutics compare to Unicycive Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Milestone Pharmaceuticals?

Summary

How does Sensei Biotherapeutics compare to Humacyte?

Summary

How does Sensei Biotherapeutics compare to NervGen Pharma?

Summary

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (FTH) Competitors

FTH vs. UNCY, MIST, HUMA, NGEN, and HURA

How does Sensei Biotherapeutics compare to Unicycive Therapeutics?

Which has more risk & volatility, UNCY or FTH?

Do analysts rate UNCY or FTH?

Which has preferable earnings and valuation, UNCY or FTH?

Do institutionals and insiders have more ownership in UNCY or FTH?

Is UNCY or FTH more profitable?

Does the media prefer UNCY or FTH?

Summary

How does Sensei Biotherapeutics compare to Milestone Pharmaceuticals?

Do analysts rate FTH or MIST?

Which has more volatility & risk, FTH or MIST?

Is FTH or MIST more profitable?

Does the media refer more to FTH or MIST?

Which has higher earnings & valuation, FTH or MIST?

Do insiders and institutionals hold more shares of FTH or MIST?

Summary

How does Sensei Biotherapeutics compare to Humacyte?

Do analysts rate HUMA or FTH?

Which has more volatility & risk, HUMA or FTH?

Is HUMA or FTH more profitable?

Does the media favor HUMA or FTH?

Do institutionals & insiders have more ownership in HUMA or FTH?

Which has stronger valuation and earnings, HUMA or FTH?

Summary

How does Sensei Biotherapeutics compare to NervGen Pharma?

Which has stronger earnings and valuation, NGEN or FTH?

Do analysts prefer NGEN or FTH?

Is NGEN or FTH more profitable?

Does the media prefer NGEN or FTH?

Do insiders & institutionals have more ownership in NGEN or FTH?

Summary

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

Is HURA or FTH more profitable?

Does the media prefer HURA or FTH?

Do analysts prefer HURA or FTH?

Do insiders and institutionals have more ownership in HURA or FTH?

Which has better valuation and earnings, HURA or FTH?

Which has more risk and volatility, HURA or FTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools